Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 3:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Control Therapy Clear all
Suspended Not applicable Interventional

A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination

NCT06168942
View directory record Official record
Conditions
Non-valvular Atrial Fibrillation, Stroke, Systemic Embolism
Interventions
Experimental: Laminar Left Atrial Appendage Closure System, Active Comparator: WATCHMAN / Amulet
Device
Lead sponsor
Biosense Webster, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 25, 2026, 3:12 AM EDT
Completed Not applicable Interventional

A Comprehensive Self-Management Intervention for Individuals With Inflammatory Bowel Disease

NCT05651542
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions
Comprehensive Self-Management Intervention, Control
Behavioral · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 25, 2026, 3:12 AM EDT
Completed Phase 3 Interventional

Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents

NCT00115570
View directory record Official record
Conditions
Diabetes Mellitus, Insulin-Dependent
Interventions
Insulin glulisine, insulin lispro, insulin glargine, NPH insulin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
4 Years to 17 Years
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Sep 25, 2026, 3:12 AM EDT
Completed Not applicable Interventional

Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus

NCT01839370
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Closed Loop with Pramlintide
Device
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 18, 2014 · Synced Sep 25, 2026, 3:12 AM EDT
Completed Phase 3 Interventional

Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency

NCT01406470
View directory record Official record
Conditions
Immunologic Deficiency Syndrome
Interventions
Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™
Drug
Lead sponsor
Green Cross Corporation
Industry
Eligibility
2 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Birmingham, Alabama • North Palm Beach, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Sep 25, 2026, 3:12 AM EDT
Active, not recruiting Not applicable Interventional

Improving Patient and Family Health Using Family-Centered Outcomes and Shared Decision-Making

NCT04437069
View directory record Official record
Conditions
Patient Decision Aids, Congenital Heart Disease, Congenital Heart Defect
Interventions
Decision Aid, Values Clarification Exercise
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 25, 2026, 3:12 AM EDT
Completed Phase 2 Interventional Results available

A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model

NCT03231969
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Bilastine 0.2%, Bilastine 0.4%, Bilastine 0.6%, Bilastine 0%
Drug
Lead sponsor
Faes Farma, S.A.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Sep 25, 2026, 3:12 AM EDT
Completed Phase 3 Interventional Results available

Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections

NCT00466817
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Placebo, Valganciclovir
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 30 Days
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Sep 25, 2026, 3:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Support for Caregivers of Older Adults With Cognitive Decline

NCT04787068
View directory record Official record
Conditions
Caregiver Burden, Depression, Confidence, Self, Cognition, Fatigue, Function
Interventions
Occupational Therapy support
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2021 · Synced Sep 25, 2026, 3:12 AM EDT
Completed Phase 3 Interventional Results available

MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

NCT01792518
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Linagliptin 5mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
15
States / cities
Birmingham, Alabama • Long Beach, California • North Hollywood, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 25, 2026, 3:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

LearningRx Brain Training for Children 8-14

NCT02927197
View directory record Official record
Conditions
Learning Problems
Interventions
LearningRx cognitive training
Behavioral
Lead sponsor
Gibson Institute of Cognitive Research
Industry
Eligibility
8 Years to 14 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Sep 25, 2026, 3:12 AM EDT
Completed Not applicable Interventional Results available

Prevena™ Incisional Negative Pressure Wound Therapy in Re-operative Colorectal Surgery

NCT02509260
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Prevena wound management system, Standard wound dressings
Device · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 25, 2026, 3:12 AM EDT
Completed Phase 2 Interventional Results available

P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris

NCT02242760
View directory record Official record
Conditions
Acne Vulgaris
Interventions
SB204 2%, SB204 4%, Vehicle Gel
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
20
States / cities
Hot Springs, Arkansas • Encinitas, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Sep 25, 2026, 3:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics Study of CARD-024 in Healthy Subjects

NCT01757860
View directory record Official record
Conditions
Drug Safety, Heart; Disease, Activity
Interventions
CARD-024, Drug Carrier
Drug · Other
Lead sponsor
Cardiavent Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 30, 2012 · Synced Sep 25, 2026, 3:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Mindfulness Based Cognitive Therapy (MBCT) Resiliency Program for Critical Care Nurses

NCT03132220
View directory record Official record
Conditions
Burn-Out Syndrome, Work-Related Stress Disorder
Interventions
Mindfulness-Based Cognitive Therapy, Book Club Active Control Intervention
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Sep 25, 2026, 3:12 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy of PEAR-004 in Schizophrenia

NCT03751280
View directory record Official record
Conditions
Schizophrenia
Interventions
PEAR-004, Sham
Device
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Garden Grove, California • Oakland, California • Torrance, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 25, 2026, 3:12 AM EDT
Completed Not applicable Interventional Results available

Waitlist-Control Trial of Smartphone Cognitive Behavioral Therapy (CBT) for Body Dysmorphic Disorder (BDD)

NCT03673046
View directory record Official record
Conditions
Body Dysmorphic Disorder
Interventions
Smartphone-delivered cognitive behavioral therapy (CBT) for body dysmorphic disorder (BDD)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Sep 25, 2026, 3:12 AM EDT
Completed Not applicable Interventional Results available

Integrated CBT-I and PE on Sleep and PTSD Outcomes (Impact Study)

NCT02774642
View directory record Official record
Conditions
Posttraumatic Stress Disorders, Chronic Insomnia
Interventions
CBTI-PE, Hygiene-PE
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
19 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 25, 2026, 3:12 AM EDT
Active, not recruiting Phase 1 Interventional

A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)

NCT06436742
View directory record Official record
Conditions
Congenital Myasthenic Syndrome, CMS
Interventions
ARGX-119, Placebo
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Sacramento, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 25, 2026, 3:12 AM EDT
Completed Phase 3 Interventional

A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma

NCT00395070
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Allovectin-7®, Dacarbazine (DTIC), Temozolomide (TMZ)
Biological · Drug
Lead sponsor
Vical
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
27
States / cities
Tucson, Arizona • Little Rock, Arkansas • Bakersfield, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Sep 25, 2026, 3:12 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

NCT07174310
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Prasinezumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 25, 2026, 3:12 AM EDT
Terminated Phase 3 Interventional

EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer

NCT00574860
View directory record Official record
Conditions
Oral Mucositis, Head and Neck Cancer
Interventions
EN3285, Placebo, Standard of care
Drug · Other
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Louisville, Kentucky • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 25, 2026, 3:12 AM EDT
Completed Early Phase 1 Interventional

Towards Enhanced Recovery After Cesarean

NCT04612920
View directory record Official record
Conditions
Cesarean Section Complications
Interventions
Ibuprofen, acetaminophen, oxycodone
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Sep 25, 2026, 3:12 AM EDT
Completed Phase 2 Interventional

Norketotifen for the Treatment of Uncomplicated Influenza-like Illness

NCT04043923
View directory record Official record
Conditions
Influenza -Like Illness
Interventions
Norketotifen, Placebo
Drug
Lead sponsor
Emergo Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 25, 2026, 3:12 AM EDT